SG10201408073XA - Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target - Google Patents
Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given targetInfo
- Publication number
- SG10201408073XA SG10201408073XA SG10201408073XA SG10201408073XA SG10201408073XA SG 10201408073X A SG10201408073X A SG 10201408073XA SG 10201408073X A SG10201408073X A SG 10201408073XA SG 10201408073X A SG10201408073X A SG 10201408073XA SG 10201408073X A SG10201408073X A SG 10201408073XA
- Authority
- SG
- Singapore
- Prior art keywords
- muteins
- hngal
- lcn2
- affinity
- given target
- Prior art date
Links
- 101001023833 Homo sapiens Neutrophil gelatinase-associated lipocalin Proteins 0.000 title abstract 3
- 102000047202 human LCN2 Human genes 0.000 title abstract 3
- 101150055061 LCN2 gene Proteins 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
- 102000016359 Fibronectins Human genes 0.000 abstract 1
- 108010067306 Fibronectins Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00041—Use of virus, viral particle or viral elements as a vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Marine Sciences & Fisheries (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26709809P | 2009-12-07 | 2009-12-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201408073XA true SG10201408073XA (en) | 2015-01-29 |
Family
ID=43597993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201408073XA SG10201408073XA (en) | 2009-12-07 | 2010-12-07 | Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9549968B2 (zh) |
| EP (3) | EP2990798B1 (zh) |
| JP (5) | JP5913120B2 (zh) |
| KR (2) | KR101974044B1 (zh) |
| CN (1) | CN102770764B (zh) |
| AU (1) | AU2010329995B2 (zh) |
| BR (1) | BR112012013662B1 (zh) |
| CA (1) | CA2779562C (zh) |
| DK (2) | DK2510357T3 (zh) |
| RU (2) | RU2707126C2 (zh) |
| SG (1) | SG10201408073XA (zh) |
| WO (1) | WO2011069992A2 (zh) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2779562C (en) | 2009-12-07 | 2019-12-31 | Pieris Ag | Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target |
| KR20180088745A (ko) * | 2010-08-16 | 2018-08-06 | 피어이스 파마슈티컬즈 게엠베하 | 헵시딘 결합 단백질 |
| WO2013113851A1 (en) | 2012-01-31 | 2013-08-08 | Technische Universitaet Muenchen | Muteins of a1m lipocalin and method of production therefor |
| WO2013174783A1 (en) * | 2012-05-23 | 2013-11-28 | Pieris Ag | Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3 |
| US10526384B2 (en) | 2012-11-19 | 2020-01-07 | Pieris Pharmaceuticals Gmbh | Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof |
| JP6753784B2 (ja) | 2014-05-22 | 2020-09-09 | ピエリス ファーマシューティカルズ ゲーエムベーハー | 特異的結合ポリペプチドおよびその使用 |
| BR112017015773A2 (pt) | 2015-01-28 | 2018-03-27 | Pieris Pharmaceuticals Gmbh | muteína de lipocalina, muteína de hngal, molécula de ácido nucleico, célula hospedeira, método para produzir a muteína de hngal, composição farmacêutica, kit, uso da muteína de hngal, uso da muteína de hngal, método para ligar ang-2 em um indivíduo, método para inibir angiogênese em um indivíduo, método para tratar, prevenir ou melhorar uma doença e método para inibir ou reduzir angiogênese em um indivíduo |
| EP3064507A1 (en) | 2015-03-06 | 2016-09-07 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof |
| SG11201708334RA (en) | 2015-05-04 | 2017-11-29 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
| CN114573680A (zh) * | 2015-05-04 | 2022-06-03 | 皮里斯制药有限公司 | Cd137特异性的蛋白 |
| SG11201707872WA (en) * | 2015-05-18 | 2017-10-30 | Pieris Pharmaceuticals Gmbh | Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) |
| SI3298030T1 (sl) | 2015-05-18 | 2023-05-31 | Pieris Pharmaceuticals Gmbh | Protirakav fuzijski polipeptid |
| EP3115371A1 (en) | 2015-07-07 | 2017-01-11 | Sanofi | Fusion molecules |
| CN108699162A (zh) * | 2015-11-30 | 2018-10-23 | 皮里斯澳大利亚有限公司 | 新型抗血管生成融合多肽 |
| TW201725212A (zh) * | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
| EP3485277A1 (en) | 2016-07-18 | 2019-05-22 | Philippe Ulsemer | Natural microorganisms which are naturally capable of binding toxins and/or toxin receptors |
| GB201615254D0 (en) * | 2016-09-08 | 2016-11-23 | Ge Healthcare Bio Sciences Ab | Novel Ligand and use thereof |
| CN107403074B (zh) * | 2017-06-09 | 2018-05-29 | 天津市湖滨盘古基因科学发展有限公司 | 一种突变蛋白的检测方法及装置 |
| EP3715370A1 (en) * | 2019-03-28 | 2020-09-30 | Technische Universität München | High affinity anticalins directed against human cd98hc |
| JP2022526367A (ja) | 2019-03-29 | 2022-05-24 | ピエリス ファーマシューティカルズ ゲーエムベーハー | リポカリンムテインの吸入投与 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| ES2032831T5 (es) | 1986-08-19 | 2001-02-16 | Genentech Inc | Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas. |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| NZ285664A (en) | 1994-05-18 | 1998-07-28 | Inhale Therapeutic Syst | Dry powder interferon composition adapted for pulmonary delivery |
| DE4417598A1 (de) | 1994-05-19 | 1995-12-14 | Max Planck Gesellschaft | Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen |
| AU5132096A (en) | 1995-01-30 | 1996-08-21 | Terrapin Technologies, Inc. | Glubodies - multiplicities of proteins capable of binding a variety of small molecules |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
| WO1998016873A1 (fr) | 1996-10-14 | 1998-04-23 | Firm Forsat Ltd. | Procede de preparation de dispersions a base de composants chromogenes |
| WO1999007740A2 (en) | 1997-08-06 | 1999-02-18 | Zymogenetics, Inc. | Lipocalin homologs |
| US20140080177A1 (en) | 1997-09-26 | 2014-03-20 | Pieris Ag | Anticalins |
| DE19742706B4 (de) * | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| RS50144B (sr) | 1998-06-08 | 2009-03-25 | F. Hoffmann-La Roche Ag., | Primena peg-inf-alfa 2a i ribavirina za proizvodnju leka za lečenje hroničnog hepatitisa c |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| CA2343917A1 (en) | 1998-10-19 | 2000-04-27 | Ariad Gene Therapeutics, Inc. | Materials and methods involving conditional retention domains |
| AU781292B2 (en) * | 1999-03-04 | 2005-05-12 | Praecis Pharmaceuticals Incorporated | Modulators of beta-amyloid peptide aggregation comprising D-amino acids |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| WO2002076489A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
| WO2003029462A1 (en) * | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| CA2464690A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of apolipoprotein d |
| EP1658308A1 (en) | 2003-08-25 | 2006-05-24 | Pieris ProteoLab AG | Muteins of a bilin-binding protein with affinity for a given target |
| AU2003275958A1 (en) * | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| JP2007284351A (ja) | 2004-07-27 | 2007-11-01 | Osaka Bioscience Institute | アミロイド蛋白質の凝集を抑制する物質とその作用 |
| US7892827B2 (en) | 2004-11-26 | 2011-02-22 | Pieris Ag | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| JP2009509535A (ja) | 2005-09-27 | 2009-03-12 | アムニクス， インコーポレイテッド | タンパク様薬剤およびその使用 |
| ES2354653T3 (es) * | 2006-08-01 | 2011-03-16 | Pieris Ag | Muteínas de lipocalina lacrimal y procedimientos para obtener las mismas. |
| EP2046820B1 (en) * | 2006-08-01 | 2010-10-20 | Pieris AG | Muteins of tear lipocalin and methods for obtaining the same |
| EP2225268B1 (en) * | 2007-10-19 | 2012-08-29 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
| EP2313430B1 (en) | 2008-06-24 | 2018-05-02 | Technische Universität München | Muteins of hngal and related proteins with affinity for a given target |
| CA2779562C (en) | 2009-12-07 | 2019-12-31 | Pieris Ag | Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target |
| KR20180088745A (ko) * | 2010-08-16 | 2018-08-06 | 피어이스 파마슈티컬즈 게엠베하 | 헵시딘 결합 단백질 |
| US9260492B2 (en) | 2010-11-15 | 2016-02-16 | Pieris Ag | Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3) |
| US10526384B2 (en) * | 2012-11-19 | 2020-01-07 | Pieris Pharmaceuticals Gmbh | Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof |
| BR112017015773A2 (pt) | 2015-01-28 | 2018-03-27 | Pieris Pharmaceuticals Gmbh | muteína de lipocalina, muteína de hngal, molécula de ácido nucleico, célula hospedeira, método para produzir a muteína de hngal, composição farmacêutica, kit, uso da muteína de hngal, uso da muteína de hngal, método para ligar ang-2 em um indivíduo, método para inibir angiogênese em um indivíduo, método para tratar, prevenir ou melhorar uma doença e método para inibir ou reduzir angiogênese em um indivíduo |
| TW201636364A (zh) | 2015-02-18 | 2016-10-16 | 賽諾菲公司 | 對於螢光鐵載體及綠膿桿菌螯鐵蛋白具特異性之新穎蛋白 |
| CN114573680A (zh) | 2015-05-04 | 2022-06-03 | 皮里斯制药有限公司 | Cd137特异性的蛋白 |
| SG11201707872WA (en) | 2015-05-18 | 2017-10-30 | Pieris Pharmaceuticals Gmbh | Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) |
| TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
-
2010
- 2010-12-07 CA CA2779562A patent/CA2779562C/en active Active
- 2010-12-07 KR KR1020187007781A patent/KR101974044B1/ko active IP Right Grant
- 2010-12-07 BR BR112012013662-3A patent/BR112012013662B1/pt active IP Right Grant
- 2010-12-07 KR KR1020127017730A patent/KR101842076B1/ko active IP Right Grant
- 2010-12-07 DK DK10784824.4T patent/DK2510357T3/en active
- 2010-12-07 CN CN201080055370.5A patent/CN102770764B/zh active Active
- 2010-12-07 EP EP15186647.2A patent/EP2990798B1/en active Active
- 2010-12-07 EP EP19198835.1A patent/EP3660510A3/en active Pending
- 2010-12-07 AU AU2010329995A patent/AU2010329995B2/en active Active
- 2010-12-07 SG SG10201408073XA patent/SG10201408073XA/en unknown
- 2010-12-07 RU RU2015137158A patent/RU2707126C2/ru active
- 2010-12-07 EP EP10784824.4A patent/EP2510357B1/en active Active
- 2010-12-07 US US13/514,133 patent/US9549968B2/en active Active
- 2010-12-07 RU RU2012128586/10A patent/RU2564125C2/ru active
- 2010-12-07 DK DK15186647T patent/DK2990798T3/da active
- 2010-12-07 WO PCT/EP2010/069028 patent/WO2011069992A2/en active Application Filing
- 2010-12-07 JP JP2012542505A patent/JP5913120B2/ja active Active
-
2015
- 2015-12-02 JP JP2015236010A patent/JP6346159B2/ja active Active
-
2016
- 2016-12-15 US US15/380,168 patent/US10618941B2/en active Active
-
2018
- 2018-05-24 JP JP2018099240A patent/JP2018148914A/ja active Pending
-
2020
- 2020-03-06 US US16/812,069 patent/US11827681B2/en active Active
- 2020-07-07 JP JP2020117175A patent/JP2021006024A/ja active Pending
-
2022
- 2022-07-01 JP JP2022106985A patent/JP7482544B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201408073XA (en) | Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target | |
| Buckley | Species identification of bovine, ovine and porcine type 1 collagen; comparing peptide mass fingerprinting and LC-based proteomics methods | |
| WO2007067730A3 (en) | Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use | |
| SG170080A1 (en) | Human monoclonal antibodies to o8e | |
| MX2010004915A (es) | Anticuerpos para gdf8 asi como sus usos. | |
| WO2007067992A3 (en) | Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 | |
| EA201690946A1 (ru) | Мутанты fgf21 и их применение | |
| EA201171220A1 (ru) | Мутанты fgf21 и их применение | |
| UA97473C2 (ru) | Выделенное антитело, которое связывается с her-3, и его применение | |
| MX2010000537A (es) | Anticuerpos monoclonales contra glipicano-3. | |
| MX2009002816A (es) | Proteinas de fusion de albumina. | |
| MX2009005189A (es) | Anticuerpos humanos monoclonales para btla y metodos de uso. | |
| SG163554A1 (en) | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) | |
| MX2008001865A (es) | Proteinas de fusion de albumina. | |
| UA113609C2 (xx) | Антигензв'язуючий білок, який зв'язує людський il-23 | |
| MX2010008570A (es) | Anticuerpos alfa5-beta1 y sus usos. | |
| MY177065A (en) | 4-1bb binding molecules | |
| WO2006089230A3 (en) | Human monoclonal antibodies to prostate specific membrane antigen (psma) | |
| EA201990619A1 (ru) | Fgf21 мутанты и их применение | |
| MX2009002418A (es) | Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso. | |
| EA200901436A1 (ru) | Антигенсвязывающие белки, связывающие par-2 | |
| MX2008009886A (es) | Anticuerpos que enlazan par-2. | |
| MX2012005864A (es) | Proteinas de enlace al antígeno anti-orai 1 y usos de las mismas. | |
| EA201290849A1 (ru) | Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
| EA201290069A1 (ru) | Модифицированные полипептиды фактора ix и их применения |